Clinical trial

Sequential Immune Modulation and Antigen-Specific Tolerance Induction for Disease Modification in Recent-Onset Type 1 Diabetes

NCT07610213

StatusNOT_YET_RECRUITING

Study typeINTERVENTIONAL

Start date2027-01-01

PhasePHASE1

Study timeline

Study start (estimated)2027-01-01Date precision: day

Registry last updated2026-05-27

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

Type 1 Diabetes Mellitus (T1DM)unresolved

Type 1 Diabetes Mellitusunresolved

Autoimmune Diabetesunresolved

Interventions

TeplizumabDRUG · verified · RxNorm: teplizumab

Intralymphatic Insulin Immunotherapy (ILIT)BIOLOGICAL

Sponsors & collaborators

Abdullah Karslead sponsor

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT07610213 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.